Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: gbh who wrote (714)	11/24/1999 1:33:00 PM
From: All Mtn Ski	Respond to of 10345

The Street is now focusing away from the drug delay and more on the underlying earnings story, which is powerful, IMHO. Perhaps a little bit of takeover speculation thrown in for good measure. Go ELN!! Tom

To: gbh who wrote (714)	11/24/1999 4:14:00 PM
From: lazarre	Respond to of 10345

Look at the PE; it's absurd. WLA/PFE/AHP: 3 mega giants. Whatever shakes out, all pharmas effected, including ELN. How? Beats me. But it has a pipeline, it has state of art mgg and R&D, and its in Europe. L

To: gbh who wrote (714)	11/24/1999 7:37:00 PM
From: Gary Korn	Read Replies (1) \| Respond to of 10345

Anyone have explanation for today's move? The stock just keeps moving higher on heavy volume. Gary, Perhaps there is impending Zonagren news. Regardless, you can only hold a value play down for so long. With a growth rate of some 25 percent, this stock just shouldn't be trading at 28. It is fairly valued at 40 at a minimum. I just keep recalling what the CFO stated: "Revenues will be $2 billion or double the current number by 2003." Even without p.e. expansion, that makes for a $56 stock. Be patient. Gary Korn

To: gbh who wrote (714)	11/24/1999 7:47:00 PM
From: Gary Korn	Respond to of 10345

From the YHOO board: Alzheimer's drug AN-1792 by: broodje1 11/24/1999 3:10 pm EST Msg: 4158 of 4166 "During the DLJ Health Care Conference, Elan confirmed that sales for 1999 are expected to achieve a level of about $980 million and that earnings remain on-track"...Elan indicated that the filing for its new anti-Alzheimer's disease drug (AN-1792) has passed initial IND (Investigational New Drug) review by the FDA. Elan expects to start U.S. human clinical safety trials shortly. European clinical studies are also expected 2nd qtr 2000... Full efficacy trials toward end of 2000...fast track status.

To: gbh who wrote (714)	11/24/1999 7:49:00 PM
From: Gary Korn	Respond to of 10345

From the YHOO board: diogenes112358 by: HMCCPO 11/24/1999 6:51 pm EST Msg: 4165 of 4166 Here's what A.G. Edwards has to say about Ziconotide: "Ziconotide, SNX-111 from Neurox, is a neuron-specific calcium channel blocker for chronic and acute pain. As a nonopiate, it does not exhibit some of the negative side effects of drugs like morphine For chronic malignant or nonmalignant pain, ELN is working with Medtronic to deliver the drug intrathecally (into the spinal cord) via an implantation and programmable delivery pump. Phase III trials are completed and additional safety studies are near completion for chronic pain. An NDA is expected by year end and a six-month FDA review is expected. A mid-2000 launch is likely and ELN will be the marketer. To treat pain without the effects to cognitive and other motor functions, we expect strong market acceptance. ELN is also testing ziconotide in Phase II trials for acute, surgical pain which would be administered with an epidural injection; an NDA in 2000 is possible and a 2001 launch should follow. We believe Ziconotide could become ELN's largest product with total potential revenues of $300 million to $600 million. It could also be the largest new product contributor in 2000 and 2001."